Table 1:
Manufacturer involvement in and funding of cost-effectiveness analysis studies involving the Pap test for cervical cancer screening or prevention
| Manufacturer involvement and funding | No. (%) | ||
|---|---|---|---|
| All studies n = 109 | Studies with estimates of Pap test sensitivity and specificity n = 88 | Noneligible studies n = 21 | |
| Author affiliated with manufacturer | |||
| Yes | 19 (17.4) | 19 (21.6) | 0 (0.0) |
| No | 90 (82.6) | 69 (78.4) | 21 (100.0) |
| Funding from the manufacturer | |||
| Yes | 25 (22.9) | 25 (28.4) | 0 (0.0) |
| No | 84 (77.1) | 63 (71.6) | 21 (100.0) |
| Conflict of interest related to manufacturer | |||
| Yes | 34 (31.2) | 32 (36.4) | 2 (9.5) |
| No | 58 (53.2) | 45 (51.1) | 13 (61.9) |
| Not reported | 17 (15.6) | 11 (12.5) | 6 (28.6) |
| Author affiliation with, funding from or conflict of interest related to manufacturer* | |||
| Yes | 41 (44.6) | 39 (49.4) | 2 (15.4) |
| No | 51 (55.4) | 40 (50.6) | 11 (84.6) |
| Other (nonmanufacturer) funding reported | |||
| Yes | 50 (45.9) | 41 (46.6) | 9 (42.9) |
| No | 59 (54.1) | 47 (53.4) | 12 (57.1) |
*
Studies were excluded if they did not contain a conflict of interest statement, declared no conflict of interest, did not have an author affiliated with the manufacturer, and did not receive funding from the manufacturer.